PubRank

IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients. (IDOvaccine)

Clinical Trial ID NCT01219348

PubWeight™ 18.77‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01219348

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 2010 2.01
2 Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013 1.35
3 Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012 1.30
4 The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 2014 1.18
5 Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012 1.17
6 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
7 Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. Clin Cancer Res 2015 1.09
8 Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 2013 1.05
9 Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2013 1.04
10 Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase. PLoS One 2012 1.02
11 Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014 1.01
12 T and NK cells: two sides of tumor immunoevasion. J Transl Med 2013 0.89
13 Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. J Natl Cancer Inst 2015 0.86
14 The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase. Cancer Immunol Immunother 2012 0.84
15 Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer 2015 0.84
16 Indoleamine 2,3-dioxygenase vaccination. Oncoimmunology 2015 0.78
17 A potential role of indoleamine 2,3-dioxygenase-specific T cells in leishmania vaccination. J Infect Dis 2011 0.76
18 Interleukin-17 and type 17 helper T cells in cancer management and research. Immunotargets Ther 2014 0.75
Next 100